POAI
Predictive Oncology Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$4.91
+6.28%Year over year
Reported trailing growth
- Revenue
- -96.3%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- -34.2%
- Operating cash flow
- -34.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -56.3%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +16.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026